DKK 411.6
(6.85%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -2.93 DKK | -1226.92% |
2022 | 0.26 DKK | -93.75% |
2021 | 4.16 DKK | 433.33% |
2020 | 0.78 DKK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.60 DKK | 25.93% |
2024 Q2 | -0.60 DKK | 0.0% |
2023 Q1 | -0.65 DKK | -235.42% |
2023 FY | - DKK | -1226.92% |
2023 Q3 | -0.81 DKK | -24.62% |
2023 Q2 | -0.65 DKK | 0.0% |
2023 Q4 | -0.81 DKK | 0.0% |
2022 Q2 | -0.29 DKK | 0.0% |
2022 Q1 | -0.29 DKK | 0.0% |
2022 FY | - DKK | -93.75% |
2022 Q3 | 0.48 DKK | 265.52% |
2022 Q4 | 0.48 DKK | 0.0% |
2021 FY | - DKK | 433.33% |
2020 FY | - DKK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ALK-Abelló A/S | 2.20 DKK | 233.182% |
Bavarian Nordic A/S | 19.23 DKK | 115.237% |
Genmab A/S | 66.64 DKK | 104.397% |
Novo Nordisk A/S | 18.67 DKK | 115.694% |
Orphazyme A/S | -0.74 DKK | -295.946% |
Pharma Equity Group A/S | -0.02 DKK | -12750.877% |
Zealand Pharma A/S | -12.44 DKK | 76.447% |